期刊文献+

奥沙利铂联合胸腺肽治疗肺癌合并恶性胸腔积液的疗效和安全性观察 预览 被引量:1

Efficacy and safety of oxaliplatin combined with thymosin in the treatment of lung cancer with malignant pleural effusion
在线阅读 下载PDF
分享 导出
摘要 目的探讨奥沙利铂联合胸腺肽治疗肺癌合并恶性胸腔积液的临床疗效及安全性。方法临床纳入本院2015年2月~2017年9月收治的68例肺癌合并恶性胸腔积液(MPE)患者作为研究对象,按不同治疗方案平分为研究组、对照组各34例。研究组在奥沙利铂治疗基础上联合胸腺肽进行胸腔给药,对照组单纯给予奥沙利铂进行治疗,并将两组治疗效果、用药后不良反应发生情况及KPS评分改善情况进行对比。结果研究组与对照组在CR、PR、NC、PD上对比差异有统计学意义(χ~2=21.095、P=0.000,χ~2=4.417、P=0.036,χ~2=8.609、P=0.003,χ~2=6.058、P=0.014);研究组用药后不良反应发生率为2.94%,显著低于对照组的11.76%(χ~2=5.712、P=0.017);研究组KPS评分改善情况明显优于对照组患者,差异有统计学意义(χ~2=8.854、P=0.003,χ~2=4.654、P=0.031,χ~2=6.058、P=0.014)。结论相较于单一用药,在奥沙利铂用药基础上给予胸腺肽进行联合治疗效果更为显著,可促进各项临床症状及体征的消退,进一步提升治疗效果,且无明显毒副反应,有利于提高患者生活质量,同时改善预后效果,具备较高临床运用价值。 Objective To explore the clinical efficacy and safety of oxaliplatin combined with thymosin in the treatment of lung cancer with malignant pleural effusion. Methods Sixty-eight patients with lung cancer complicated with malignant pleural effusion(MPE) in our hospital from February 2015 to September 2017 were selected as the research subjects.The patients were divided into study group and control group according to different treatment regimens,34 cases in each group.The study group was treated with thymosin on the basis of oxaliplatin,and the control group was treated with oxaliplatin alone,and the effect of two groups,the incidence of ADR after medication and the improvement of KPS score were compared. Results The CR,PR,NC and PD of the study group and the control group had statistical differences(χ~2=21.095,P=0.000,χ~2=4.417,P=0.036,χ~2=8.609,P=0.003,χ~2=6.058,P=0.014).The incidence of adverse reactions in the study group was 2.94%,significantly lower than 11.76% in the control group(χ~2=5.712,P=0.017).The improvement of KPS score in the study group was significantly better than that of the control group(χ~2=8.854,P=0.003,χ~2=4.654,P=0.031,χ~2=6.058, P=0.014),and the comparison between the groups was statistically significant. Conclusion Compared with a single drug,the combined treatment of thymosin on the basis of oxaliplatin is more effective.It can promote the decline of various clinical symptoms and signs,further improve the therapeutic effect,and have no obvious side effects.It is beneficial to improve the quality of life and improve the prognosis, which has high clinical value.
作者 张吉发 刘希 ZHANG Jifa ,LIU Xi( Department of Hematology,Panzhihua Central Hospital,Panzhihua 617000,China)
出处 《中国医药科学》 2018年第10期36-38,138共4页 China medicine and pharmacy
关键词 奥沙利铂 胸腺肽 肺癌 恶性胸腔积液 安全性 Oxaliplatin Thymosin Lung cancer Malignant pleural effusion Safety
  • 相关文献

参考文献16

二级参考文献192

共引文献107

同被引文献8

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈